The latest update is out from ImmunoPrecise Antibodies ( (IPA) ).
ImmunoPrecise Antibodies Ltd. announced the successful completion of its ‘at-the-market’ equity offering program and the full conversion of its debenture with Yorkville Advisors, raising $7 million in proceeds. These strategic capital initiatives have significantly strengthened the company’s financial position, eliminating near-term debt obligations and enabling continued execution of its growth strategy, particularly in advancing its AI-powered therapeutic discovery platform, LENSai.
More about ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. is a biotechnology company that specializes in AI-driven antibody discovery and development. It employs multi-omics modeling and complex artificial intelligence through proprietary and patented technologies to support the development of therapeutic antibodies. The company has several subsidiaries across North America and Europe, offering an integrated end-to-end suite of capabilities to tackle complex industry challenges.
YTD Price Performance: 3.33%
Average Trading Volume: 6,247,097
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.45M
Learn more about IPA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com